Xanthinol nicotinate tablets 150 mg, 60 pcs.
If it is necessary to use cardiac glycosides simultaneously to prevent the development of bradycardia and arrhythmia, treatment should be carried out under the control of an electrocardiogram.
10-15 minutes after taking the tablet, a feeling of warmth may occur, which may be associated with paresthesia and hot flashes. These reactions may last 10-20 minutes or longer and their intensity may decrease several days after starting to take Xanthinol Nicotinate.
Use with caution in patients with arterial hypertension or labile blood pressure when concomitantly prescribing antihypertensive drugs or cardiac glycosides due to the possible risk of a significant decrease in blood pressure and/or the development of arrhythmia. Due to the vasodilatory effect of the drug, postural hypotension may occur. Due to a possible increase in the level of transaminases and alkaline phosphatase with long-term use of Xanthinol nicotinate, caution is required when prescribing it to patients with liver or kidney failure.
Use with caution in cases of severe atherosclerosis of the coronary and cerebral vessels, tachysystolic heart rhythm disturbances, and in elderly patients.
In patients with diabetes mellitus taking Xanthinol nicotinate, blood glucose levels should be determined more often than usual.
With long-term use of high doses of the drug, changes in glucose tolerance, increased levels of liver enzymes, and changes in biochemical blood parameters are possible, which requires discontinuation of the drug.
Xanthinol nicotinate should be prescribed with extreme caution to patients who have recently suffered from liver disease. This includes patients with Gilbert's syndrome, who are sensitive to the effect of nicotinic acid on the liver and are prone to a more pronounced increase in the content of unconjugated bilirubin.
Baseline studies should be performed to determine the presence of elevated serum lipid levels. Regular monitoring is necessary to determine serum lipid levels. In case of insufficient clinical response, the drug should be discontinued.
Since the drug contains lactose, it should not be used in patients with rare hereditary forms of galactose intolerance, lactase deficiency or glucose-galactose malabsorption syndrome.
Patients with a history of peptic ulcer should be prescribed Xanthinol nicotinate with extreme caution and avoid, if possible, prescribing maximum doses. Nicotinate promotes the release of histamine from mast cells and increases the secretion of hydrochloric acid in the stomach. Therefore, caution must be exercised in patients with hypersensitivity to irritation of the gastrointestinal tract, with bronchial asthma and with a tendency to allergies.
Buy Xanthinol nicotinate injection solution 15% 2ml No. 10 in pharmacies
Instructions for use of Xanthinol nicotinate solution d/in. 15% 2ml No. 10
Dosage forms injection solution 15% 2ml Group Antispasmodics - purine derivatives International nonproprietary name Xanthinol nicotinate Composition Active ingredient - Xanthinol nicotinate. Manufacturers : Dalkhimfarm (Russia), Moskhimfarmpreparaty im. ON THE. Semashko (Russia), Novosibkhimpharm (Russia) Pharmacological action Has a vasodilator, antiaggregation, antiatherosclerotic effect. Blocks adenosine receptors and phosphodiesterase, increasing the level of cAMP in the cell, substrate stimulates the synthesis of nicotine adenine dinucleotide (NAD) and NAD-phosphate (nicotinic acid). Has a vasodilating effect, reduces total peripheral vascular resistance, inhibits platelet aggregation, improves microcirculation, oxygenation and tissue nutrition, enhances cerebral circulation, reduces blood viscosity, activates fibrinolysis; with prolonged use, it can delay the development of atherosclerosis, reduce the level of cholesterol and atherogenic lipids, and enhance the activity of lipoprotein lipase. Side effects : Arterial hypotension, transient sensation of warmth, redness of the skin, weakness, dizziness, nausea, diarrhea, anorexia, gastralgia. With long-term administration of high doses - decreased glucose tolerance, increased activity of liver transaminases and alkaline phosphatase, hyperuricemia. Indications for use Cerebrovascular insufficiency, atherosclerosis of cerebral vessels, cerebrovascular accidents, obliterating atherosclerosis of the vessels of the lower extremities, Raynaud's disease, Buerger's disease, obliterating endarteritis, acute arterial thrombosis, diabetic angiopathy, retinopathy, acute thrombophlebitis (superficial and deep veins), postthrombophlebitis syndrome, trophic ulcers of the lower extremities, bedsores, migraines, Meniere's syndrome, dermatoses (due to impaired trophism of vascular origin), atherosclerosis of the coronary vessels, hypercholesterolemia, hypertriglyceridemia, intrauterine and postpartum fetal asphyxia. Contraindications Hypersensitivity, severe congestive heart failure, acute bleeding, acute myocardial infarction, gastric and duodenal ulcers in the acute stage. Restrictions on use: arterial hypotension, pregnancy (especially in the 1st trimester). Method of administration and dosage: 2-6 ml of 15% solution is administered intramuscularly for 2-3 weeks. IV stream - 2 ml of 15% solution 1-2 times a day for 5-10 days (the patient should be in a horizontal position). Injected intravenously at a rate of 40-50 drops/min, diluting 10 ml of a 15% solution in 200-500 ml of a 5% glucose solution or in 200 ml of isotonic sodium chloride solution. Overdose No data available. Interaction Strengthens (mutually) the effect of antihypertensive drugs (beta-blockers, ergot alkaloids, alpha-blockers, sympatholytics, ganglion blockers). Special instructions Caution should be exercised when administered concomitantly with antihypertensive drugs and strophanthin. Storage conditions : Protected from light, at room temperature.
Xanthinol nicotinate tablets 150 mg No. 10x6
Name
Xanthinol nicotinate tab. 150 mg per bl. in pack №10x6
Description
Pills
Main active ingredient
Xanthinol nicotinate
Release form
Tablets 150 mg, 10 tablets in a blister, 6 blisters in a pack.
Dosage
150 mg per bl. in pack №10x6
Pharmacodynamics
Vasodilator, antiaggregation, antiatherosclerotic agent, combines the properties of theophylline and nicotinic acid. Blocks adenosine receptors and phosphodiesterase, increasing the level of cyclic adenosine monophosphoric acid in the cell, substrate stimulates the synthesis of nicotine adenine dinucleotide and nicotine adenine dinucleotide phosphate. Has a vasodilating effect, reducing the total peripheral vascular resistance and improving microcirculation, oxygenation and tissue nutrition, reduces blood viscosity; activates cerebral circulation; inhibits platelet aggregation, activates fibrinolysis; increases heart contraction. With long-term use, it can delay the development of atherosclerotic changes, reduce the level of cholesterol and atherogenic lipids, and increase the activity of lipoprotein lipase. With long-term use, it can reduce blood pressure.
Pharmacokinetics
It is well absorbed in the digestive tract and breaks down to form xanthinol and nicotinic acid. Metabolized in the liver. It is excreted in the urine, mainly in the form of metabolites.
Indications for use
Symptomatic treatment of vasospastic disorders such as Raynaud's disease and syndrome. The drug in this dosage form should be used at the end of the acute phase of the process. Hypercholesterolemia or hypercholesterolemia with hypertriglyceridemia, as an addition to diet and other measures to correct hyperlipidemia, when the effect of these measures is insufficient.
Directions for use and doses
Administer orally to adults after meals. Swallow the tablets without chewing. The initial dose is usually 1 tablet (150 mg) 3 times a day. If necessary, increase the single dose to 2-3 tablets (300-450 mg) 3 times a day, then, as the condition improves, reduce the dose to 1 tablet 2-3 times a day. The maximum daily dose if therapy is well tolerated is 12 tablets (1800 mg). The course of treatment is determined by the doctor depending on the course of the disease and tolerability of the drug. In case of acute peripheral circulatory disorders, preference is given to the injection form of the drug.
Precautionary measures
If it is necessary to use cardiac glycosides simultaneously to prevent the development of bradycardia and arrhythmia, treatment should be carried out under the control of an electrocardiogram. 10-15 minutes after taking the tablet, a feeling of warmth may occur, which may be associated with paresthesia and hot flashes. These reactions may last 10-20 minutes or longer and their intensity may decrease several days after starting to take Xanthinol Nicotinate. Use with caution in patients with arterial hypertension or labile blood pressure when concomitantly prescribing antihypertensive drugs or cardiac glycosides due to the possible risk of a significant decrease in blood pressure and/or the development of arrhythmia. Due to the vasodilatory effect of the drug, postural hypotension may occur. Due to a possible increase in the level of transaminases and alkaline phosphatase with long-term use of Xanthinol nicotinate, caution is required when prescribing it to patients with liver or kidney failure. Use with caution in cases of severe atherosclerosis of the coronary and cerebral vessels, tachysystolic heart rhythm disturbances, and in the elderly. In patients with diabetes mellitus taking Xanthinol nicotinate, blood glucose levels should be determined more often than usual. With long-term use of high doses of the drug, changes in glucose tolerance, increased levels of liver enzymes, and changes in biochemical blood parameters are possible, which requires discontinuation of the drug. Xanthinol nicotinate should be prescribed with extreme caution to patients who have recently suffered from liver disease. This includes patients with Gilbert's syndrome, who are sensitive to the effect of nicotinic acid on the liver and are prone to a more pronounced increase in the content of unconjugated bilirubin. Baseline studies should be performed to determine the presence of elevated serum lipid levels. Regular monitoring is necessary to determine serum lipid levels. In case of insufficient clinical response to treatment, the use of the drug should be discontinued. Since the drug contains lactose, it should not be used in patients with rare hereditary forms of galactose intolerance, lactase deficiency or glucose-galactose malabsorption syndrome. Patients with a history of peptic ulcer should be prescribed Xanthinol nicotinate with extreme caution and, if possible, avoid prescribing maximum doses. Nicotinate promotes the release of histamine from mast cells and increases the secretion of hydrochloric acid in the stomach. Therefore, caution must be exercised in patients with hypersensitivity to gastrointestinal irritation, with bronchial asthma and with a tendency to allergies. Because of the possible increase in blood uric acid levels, caution should be exercised and blood uric acid levels monitored in patients with gout. Use during pregnancy or breastfeeding The drug is not prescribed during pregnancy or breastfeeding. Children The effectiveness and safety of the drug in children have not been established, so the drug should not be used in this category of patients. The ability to influence the reaction rate when driving a vehicle or working with other mechanisms. Care must be taken when driving a vehicle or working with other mechanisms, given the possibility of developing dizziness.
Interaction with other drugs
To avoid a sharp decrease in blood pressure, the drug should not be prescribed in combination with antihypertensive drugs (beta-blockers, alpha-blockers, sympatholytics, ganglion blockers, ergot alkaloids). When used together with strophanthin and other cardiac glycosides, bradycardia and arrhythmias may occur. The drug is also incompatible with MAO inhibitors, alcohol and coffee. Enhances the anticoagulant effect of heparin, streptokinase, fibrinolysin. Use with extreme caution simultaneously with nicotine patches, as hot flashes, a feeling of heat and pulsation in the head may occur.
Contraindications
Hypersensitivity to any components of the drug, as well as to theophylline and nicotinic acid; chronic heart failure of II-III degree; acute myocardial infarction; acute renal failure; acute heart failure or severe congestive heart failure; acute bleeding; gastric and duodenal ulcers in the acute stage; glaucoma; mitral stenosis; arterial hypotension; liver failure; period of pregnancy or breastfeeding; childhood.
Compound
1 tablet contains: xanthinol nicotinate, calculated as 100% substance - 150 mg; excipients: lactose monohydrate (granulak-70); potato starch; povidone; calcium stearate.
Overdose
Symptoms: pronounced arterial hypotension, tachycardia, feeling of heat, tingling and redness of the skin of the head and neck, a feeling of squeezing in the head, weakness, dizziness, fainting, nausea, vomiting, diarrhea, gastralgia. Treatment: the patient should be laid down; These symptoms usually go away on their own after 10-15 minutes and do not require special treatment. The presence of severe arterial hypotension requires symptomatic therapy.
Side effect
From the immune system: allergic reactions, including skin rash (urticarial, erythematous-papular), itching, sensation of heat, tingling, hyperemia of the skin of the upper body, especially the neck and head, in isolated cases - angioedema. From the central and peripheral nervous system: increased fatigue, weakness, dizziness, headache. From the cardiovascular system: hot flashes, feeling of heat, arterial hypotension; palpitations, in isolated cases it is possible to provoke attacks of angina pectoris, heart rhythm disturbances, and the development of steal syndrome. From the digestive system: rarely - nausea, vomiting, diarrhea, anorexia, gastralgia, bloating, flatulence, abdominal discomfort, heartburn, recurrent ulcer. From the musculoskeletal system: muscle cramps, weakness, arthritis due to the occurrence of gout. From the skin and mucous membranes: dry skin, peeling of the epidermis, pigmentation, hyperkeratosis. From the organs of vision: blurred vision, swelling of the eyes, exophthalmos, amblyopia, cystoid macular edema. From the endocrine system: with long-term use of high doses - decreased glucose tolerance. Laboratory and instrumental data: increased liver transaminases (ALT, AST), alkaline phosphatase, LDH and ESR (erythrocyte sedimentation rate), increased uric acid levels, which contributes to the occurrence of gout, hyperglycemia.
Storage conditions
In original packaging to protect from light and moisture, at a temperature not exceeding 25 °C. Keep out of the reach of children.